Tofacitinib for Inflammatory Eye Disease

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT03580343
Phase
PHASE2
Status
Unknown

Conditions

  • Scleritis
  • Uveitis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • tofacitinib — DRUG
    tofacitinib extended release, 11mg, daily, oral

Study Details

Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.

Key Dates

Start date
Apr 4, 2019
Status verified
Jan 2021
Primary completion
Dec 1, 2019
Completion
Apr 4, 2021

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacitinib Treatment
    11mg extended-release tofacitinib, once daily, oral

Primary Outcome Measure

Treatment Failure (Composite Outcome) [ Time Frame: 180 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University in Saint LouisSt LouisMissouri63110-

Find similar trials in St Louis, MO

By research site
Washington University in Saint Louis· St Louis, MO

Related Studies